The article provides an overview about the existence and types of discounts and rebates granted to public payers by the pharmaceutical industry in European countries. Data were provided by public authorities for pharmaceutical pricing and reimbursement represented in the PPRI (Pharmaceutical Pricing and Reimbursement Information) network.Access to the full text at http://whocc.goeg.at/Publications/Articles.
Congratulations to Kees de Joncheere who was appointed as the new Director of Essential Medicines and Pharmaceuticals Policies (EMP) in WHO Headquarters in Geneva.
Kees de Joncheere was WHO Representative and Head of Country Office in Ukraine. Before, he was Regional Adviser Pharmaceuticals and Health technologies in WHO Europe.
The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies published a Spanish glossary of pharmaceutical terms with English translation of the key words.
The Spanish glossary was developed as part of our work on the development and promotion of a common understanding and language on pharmaceutical issues (see http://whocc.goeg.at/Topics/Terminology).
The PPRI project was selected by the Executive Agency for Health and Consumers, in collaboration with the Health Programme’s National Focal Points (NFP) and the Directorate General for Health and Consumers (DG SANCO) as a good practice example of a EU Public Health projects with an important impact for EU Member States.
The Austrian Health Institute published a study which analyzed the impact of pharmacy deregulation and regulation based on a survey in nine European countries. The countries investigated were countries with a deregulated community pharmacy sector (England, Ireland, the Netherlands, Norway, and Sweden) on the one hand and countries with a regulated community pharmacy sector (Austria, Denmark, Finland, and Spain) on the other hand.
The study concluded that expectations which were often connected to deregulation in the community pharmacy sector, in particular to improved accessibility and reduced medicines prices, could not be fully met. Liberalisation in the pharmacy sector can even have consequences, which might impede a good and equitable access to medicines, such as
Detailed results are available in a 250 page full report which contains:
Key outcomes and conclusions are provided in a concise 20 page summary report.